Magnetic nanoparticles as targeted delivery systems in oncology

Radiology and Oncology

Volumn 45, Issue 1, 2011, Pages 1-16

  Prijic, Sara ^a   Sersa, Gregor ^b  

^a Nanotesla Institute   (Slovenia)

^b INSTITUTE OF ONCOLOGY   (Slovenia)

Author keywords

cancer therapy; delivery systems; magnetic nanoparticles; magnetic targeting; magnetofection; nanotechnology; oncology

Indexed keywords

DRUG CARRIER; MAGNETIC NANOPARTICLE; NUCLEIC ACID;

ADULT; CASE REPORT; CELL TRANSPORT; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; GENETIC TRANSFECTION; HUMAN; HYPERTHERMIA; INTERNALIZATION; MAGNETIC FIELD; NANOTECHNOLOGY; REVIEW; SEDIMENTATION;

EID: 79952035153     PISSN: 13182099     EISSN: 15813207     Source Type: Journal    
DOI: 10.2478/v10019-011-0001-z     Document Type: Review

References (125)

1. Widder KJ, S enyei AE, Ranney DF. Magnetically responsive microspheres and other carriers for the biophysical targeting of antitumor agents. Adv Pharmacol Chemother 1979; 16: 213-71.
2. Scherer F, A nton M, Schillinger U, Henke J, Bergemann C, Krüger A, et al. Magnetofection: enhancing and targeting gene delivery by magnetic force (Pubitemid 34189525)
3. Morana G, Sal viato E, Guarise A. Contrast agents for hepatic MRI. Cancer Imaging 2007; 7 Spec No A: S24-7. (Pubitemid 350143143)
4. Kreuter J. Dr ug targeting with nanoparticles. Eur J Drug Metab Pharmacokinet 1994; 19: 253-6. (Pubitemid 24331195)
5. Filipponi L, Sutherland D, editors. Nanotechnology: a brief introduction [Internet]. Aarhus: University of Aarhus; 2007 [cited 2010 March 11]. Available from: .
6. Hunter R. Ele ctrokinetics and the zeta potential. In: Hunter R, editor. Foundations of colloid science. New York: Oxford University Press; 2001. p. 373-434.
7. Auffan M, Ros e J, Bottero JY, Lowry GV, Jolivet JP, Wiesner MR. Towards a definition of inorganic nanoparticles from an environmental, health and safety perspective. Nat Nanotechnol 2009; 4: 634-41.
8. Gubin S. Intr oduction. In: Gubin S, editor. Magnetic nanoparticles. Weinheim: Wiley-VCH; 2009. p. 1-24.
9. Bondi JF, Oyl er KD, Ke X, Schiffer P, Schaak RE. Chemical synthesis of airstable manganese nanoparticles. J Am Chem Soc 2009; 131: 9144-5.
10. Alexiou C, Jurgons R. Magnetic drug targeting. In: Andrä W, Nowak H, editors. Magnetism in medicine: a handbook. Berlin: Wiley-VCH; 2007. p. 596-605.
11. Lowery T. Nano materials-based magnetic sensors switch biosensors. In: Kumar C, editor. Nanomaterials for the life sciences. Weinheim: Wiley-VCH; 2009. p. 3-54.
12. Wilhelm C, Ceb ers A, Bacri JC, Gazeau F. Deformation of intracellular endosomes under a magnetic field. Eur Biophys J 2003; 32: 655-60. (Pubitemid 37413250)
13. Kirschvink JL, Kobayashi-Kirschvink A, Woodford BJ. Magnetite biomineralization in the human brain. Proc Natl Acad Sci U S A 1992; 89: 7683-7.
14. Schultheiss-Gr assi PP, Wessiken R, Dobson J. TEM investigations of biogenic magnetite extracted from the human hippocampus. Biochim Biophys Acta 1999; 1426: 212-6. (Pubitemid 29027884)
15. Soenen SJ, De Cuyper M. Assessing cytotoxicity of (iron oxide-based) nanoparticles: an overview of different methods exemplified with cationic magnetoliposomes. Contrast Media Mol Imaging 2009; 4: 207-19.
16. Gupta AK, Gupt a M. Synthesis and surface engineering of iron oxide nanoparticles for biomedical applications. Biomaterials 2005; 26: 3995-4021. (Pubitemid 40044762)
17. Phenrat T, Sal eh N, Sirk K, Tilton RD, Lowry GV. Aggregationnd sedimentation of aqueous nanoscale zerovalent iron dispersions. Environ Sci Technol 2007; 41: 284-90. (Pubitemid 46047855)
18. Prijic S, Scan car J, Romih R, Cemazar M, Bregar VB, Znidarsic A, et al. Increased cellular uptake of biocompatible superparamagnetic iron oxide nanoparticles into malignant cells by an external magnetic field. J Membr Biol 2010; 236: 167-79.
19. Chertok B, Dav id AE, Yang VC. Polyethyleneimine-modified iron oxide nanoparticles for brain tumor drug delivery using magnetic targeting and intra-carotid administration. Biomaterials 2010; 31: 6317-24.
20. Matsumura Y, M aeda H. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res 1986; 46: 6387-92. (Pubitemid 17221789)
21. Byrne JD, Betancourt T, Brannon-Peppas L. Active targeting schemes for nanoparticle systems in cancer therapeutics. Adv Drug Deliv Rev 2008; 60: 1615-26.
22. Leuschner C, K umar CS, Hansel W, Soboyejo W, Zhou J, Hormes J. LHRHconjugated magnetic iron oxide nanoparticles for detection of breast cancer metastases. Breast Cancer Res Treat 2006; 99: 163-76. (Pubitemid 44268264)
23. Babincova M, B abinec P. Magnetic drug delivery and targeting: principles and applications. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2009; 153: 243-50.
24. Mosso JA, Rand RW. Ferromagnetic silicone vascular occlusion: a technic for selective infarction of tumors and organs. Ann Surg 1973; 178: 663-8.
25. Lübbe AS, Berg emann C, Huhnt W, Fricke T, Riess H, Brock JW, et al. Preclinical experiences with magnetic drug targeting: tolerance and efficacy. Cancer Res 1996; 56: 4694-701. (Pubitemid 26338072)
26. Kumar A, Jena P K, Behera S, Lockey RF, Mohapatra S. Multifunctional magnetic nanoparticles for targeted delivery. Nanomedicine 2010; 6: 64-9.
27. Chouly C, Pouli quen D, Lucet I, Jeune JJ, Jallet P. Development of superparamagnetic nanoparticles for MRI: effect of particle size, charge and surface nature on biodistribution. J Microencapsul 1996; 13: 245-55. (Pubitemid 26149536)
28. Mykhaylyk O, Ze lphati O, Hammerschmid E, Anton M, Rosenecker J, Plank C. Recent advances in magnetofection and its potential to deliver siRNAs in vitro. Methods Mol Biol 2009; 487: 111-46.
29. Luo D, Saltzman WM. Enhancement of transfection by physical concentration of DNA at the cell surface. Nat Biotechnol 2000; 18: 893-5. (Pubitemid 30640918)
30. Plank C, Schill inger U, Scherer F, Bergemann C, Rémy JS, Krötz F, et al. The magnetofection method: using magnetic force to enhance gene delivery. Biol Chem 2003; 384: 737-47. (Pubitemid 36747935)
31. Huth S, Lausier J , Gersting SW, Rudolph C, Plank C, Welsch U, et al. Insights into the mechanism of magnetofection using PEI-based magnetofectins for gene transfer. J Gene Med 2004; 6: 923-36. (Pubitemid 40228108)
32. Plank C, Scherer F, Schillinger U, Bergemann C, Anton M. Magnetofection: enhancing and targeting gene delivery with superparamagnetic nanoparticles and magnetic fields. J Liposome Res 2003; 13: 29-32. (Pubitemid 36373341)
33. Gao H, Shi W, Fre und LB. Mechanics of receptor-mediated endocytosis. Proc Natl Acad Sci U S A 2005; 102: 9469-74. (Pubitemid 40981705)
34. Kim JS, Yoon TJ, Yu KN, Noh MS, Woo M, Kim BG, et al. Cellular uptake of magnetic nanoparticle is mediated through energy-dependent endocytosis in A549 cells. J Vet Sci 2006; 7: 321-6. (Pubitemid 44885830)
35. Ma YJ, Gu HC. Stu dy on the endocytosis and the internalization mechanism of aminosilane-coated Fe3O4 nanoparticles in vitro. J Mater Sci Mater Med 2007; 18: 2145-9.
36. Petri-Fink A, Cha stellain M, Juillerat-Jeanneret L, Ferrari A, Hofmann H. Development of functionalized superparamagnetic iron oxide nanoparticles for interaction with human cancer cells. Biomaterials 2005; 26: 2685-94. (Pubitemid 39600721)
37. Prabha S, Zhou WZ , Panyam J, Labhasetwar V. Size-dependency of nanoparticle- mediated gene transfection: studies with fractionated nanoparticles. Int J Pharm 2002; 244: 105-15. (Pubitemid 35245451)
38. Zauner W, Farrow NA, Haines AM. In vitro uptake of polystyrene microspheres: effect of particle size, cell line and cell density. J Control Release 2001; 71: 39-51. (Pubitemid 32195440)
39. Jordan A, Scholz R, Wust P, Schirra K, Schiestel T, Schmidt H, et al. Endocytosis of dextran and silan-coated magnetite nanoparticles and the effect of intracellular hyperthermia on human mammary carcinoma cells in vitro. J Magn Magn Mater 1999; 194: 185-96.
40. Wilhelm C, Billot ey C, Roger J, Pons JN, Bacri JC, Gazeau F. Intracellular uptake of anionic superparamagnetic nanoparticles as a function of their surface coating. Biomaterials 2003; 24: 1001-11. (Pubitemid 36024170)
41. Sincai M, Ganga D , Ganga M, Argherie D, Bica D. Antitumor effect of magnetite nanoparticles in cat mammary adenocarcinoma. J Magn Magn Mater 2005; 293: 438-41. (Pubitemid 40608963)
42. Mykhaylyk O, Ante quera YS, Vlaskou D, Plank C. Generation of magnetic nonviral gene transfer agents and magnetofection in vitro. Nat Protoc 2007; 2: 2391-411.
43. Wei W, Xu C, Wu H . Use of PEI-coated magnetic iron oxide nanoparticles as gene vectors. J Huazhong Univ Sci Technolog Med Sci 2004; 24: 618-20. (Pubitemid 41564204)
44. Chen CB, Chen JY, Lee WC. Fast transfection of mammalian cells using superparamagnetic nanoparticles under strong magnetic field. J Nanosci Nanotechnol 2009; 9: 2651-9.
45. Godbey WT, Wu KK, Mikos AG. Tracking the intracellular path of poly(ethylenimine)/DNA complexes for gene delivery. Proc Natl Acad Sci U S A 1999; 96: 5177-81. (Pubitemid 29214556)
46. Florea BI, Meaney C, Junginger HE, Borchard G. Transfection efficiency and toxicity of polyethylenimine in differentiated Calu-3 and nondifferentiated COS-1 cell cultures. AAPS PharmSci 2002; 4: E12.
47. Smith CA, de la F uente J, Pelaz B, Furlani EP, Mullin M, Berry CC. The effect of static magnetic fields and tat peptides on cellular and nuclear uptake of magnetic nanoparticles. Biomaterials 2010; 31: 4392-400.
48. Song HP, Yang JY, Lo SL, Wang Y, Fan WM, Tang XS, et al. Gene transfer using self-assembled ternary complexes of cationic magnetic nanoparticles, plasmid DNA and cell-penetrating Tat peptide. Biomaterials 2010; 31: 769-78.
49. Murata M, Takahas hi S, Kagiwada S, Suzuki A, Ohnishi S. pH-dependent membrane fusion and vesiculation of phospholipid large unilamellar vesicles induced by amphiphilic anionic and cationic peptides. Biochemistry 1992; 31: 1986-92.
50. Plank C, Zatlouka l K, Cotten M, Mechtler K, Wagner E. Gene transfer into hepatocytes using asialoglycoprotein receptor mediated endocytosis of DNA complexed with an artificial tetra-antennary galactose ligand. Bioconjug Chem 1992; 3: 533-9.
51. Green M, Loewenst ein PM. Autonomous functional domains of chemically synthesized human immunodeficiency virus tat trans-activator protein. Cell 1988; 55: 1179-88. (Pubitemid 19020070)
52. Frankel AD, Bredt DS, Pabo CO. Tat protein from human immunodeficiency virus forms a metal-linked dimer. Science 1988; 240: 70-3.
53. Xylourgidis N, Fornerod M. Acting out of character: regulatory roles of nuclear pore complex proteins. Dev Cell 2009; 17: 617-25.
54. Xu C, Xie J, Kohl er N, Walsh EG, Chin YE, Sun S. Monodisperse magnetite nanoparticles coupled with nuclear localization signal peptide for cell-nucleus targeting. Chem Asian J 2008; 3: 548-52.
55. Müller RH, Maasse n S, Weyhers H, Mehnert W. Phagocytic uptake and cytotoxicity of solid lipid nanoparticles (SLN) sterically stabilized with poloxamine 908 and poloxamer 407. J Drug Target 1996; 4: 161-70. (Pubitemid 26390298)
56. Storm G, Belliot S O, Daemen T, Lasic DD. Surface modification of nanoparticles to oppose uptake by the mononuclear phagocyte system. Adv Drug Deliv Rev 1995; 17: 31-48.
57. Jain TK, Reddy MK, Morales MA, Leslie-Pelecky DL, Labhasetwar V. Biodistribution, clearance, and biocompatibility of iron oxide magnetic nanoparticles in rats. Mol Pharm 2008; 5: 316-27.
58. Mykhaylyk O, Cherc henko A, Ilkin A, Dudchenko N, Ruditsa V, Novoseletz M, et al. Glial brain tumor targeting of magnetite nanoparticles in rats. J Magn Magn Mater 2001; 225: 241-47. (Pubitemid 32335303)
59. Kim JS, Yoon TJ, Y u KN, Kim BG, Park SJ, Kim HW, et al. Toxicity and tissue distribution of magnetic nanoparticles in mice. Toxicol Sci 2006; 89: 338-47. (Pubitemid 43013783)
60. Lacava ZGM, Azeved o RB, Lacava LM, Martins EV, Garcia VAP, Rébula CA, et al. Toxic effects of ionic magnetic fluids in mice. J Magn Magn Mater 1999; 194: 90-95.
61. Lacava LM, Garcia V AP, Kückelhaus S, Azevedo RB, Sadeghiani N, Buske N, et al. Long-term retention of dextran-coated magnetite nanoparticles in the liver and spleen. J Magn Magn Mater 2004; 272-276: 2434-35. (Pubitemid 41066985)
62. Olden K, editor. Hea lth effects from exposure to power-line frequency electric and magnetic fields [Internet]. Research triangle park (NC): National institute of environmental health sciences (US); 1999 [cited 2010 April 15]. Available from: .
63. Leszczynski D. Rappo rteur report: cellular, animal and epidemiological studies of the effects of static magnetic fields relevant to human health. Prog Biophys Mol Biol 2005; 87: 247-53. (Pubitemid 39527103)
64. Saunders R. Static m agnetic fields: animal studies. Prog Biophys Mol Biol 2005; 87: 225-39. (Pubitemid 39527101)
65. Sato K, Yamaguchi H, Miyamoto H, Kinouchi Y. Growth of human cultured cells exposed to a non-homogeneous static magnetic field generated by Sm-Co magnets. Biochim Biophys Acta 1992; 1136: 231-8.
66. Nakahara T, Yaguchi H, Yoshida M, Miyakoshi J. Effects of exposure of CHO-K1 cells to a 10-T static magnetic field. Radiology 2002; 224: 817-22. (Pubitemid 34919819)
67. Coletti D, Teodori L , Albertini MC, Rocchi M, Pristerá A, Fini M, et al. Static magnetic fields enhance skeletal muscle differentiation in vitro by improving myoblast alignment. Citometry PartA 2007; 71A: 846-56. (Pubitemid 47606741)
68. Kotani H, Kawaguchi H, Shimoaka T, Iwasaka M, Ueno S, Ozawa H, et al. Strong static magnetic field stimulates bone formation to a definite orientation in vitro and in vivo. J Bone Miner Res 2002; 17: 1814-21.
69. Sun C, Lee JS, Zhang M . Magnetic nanoparticles in MR imaging and drug delivery. Adv Drug Deliv Rev 2008; 60: 1252-65.
70. Saini S, Stark DD, Hah n PF, Wittenberg J, Brady TJ, Ferrucci JT. Ferrite particles: a superparamagnetic MR contrast agent for the reticuloendothelial system. Radiology 1987; 162: 211-6. (Pubitemid 17001812)
71. Saini S, Stark DD, Hah n PF, Bousquet JC, Introcasso J, Wittenberg J, et al. Ferrite particles: a superparamagnetic MR contrast agent for enhanced detection of liver carcinoma. Radiology 1987; 162: 217-22. (Pubitemid 17001813)
72. Weissleder R, Stark DD . Magnetic resonance imaging of liver tumors. Semin Ultrasound CT MR 1989; 10: 63-77. (Pubitemid 19061566)
73. Weissleder R, Elizondo G, Wittenberg J, Rabito CA, Bengele HH, Josephson L. Ultrasmall superparamagnetic iron oxide: characterization of a new class of contrast agents for MR imaging. Radiology 1990; 175: 489-93. (Pubitemid 20135290)
74. Chertok B, David AE, M offat BA, Yang VC. Substantiating in vivo magnetic brain tumor targeting of cationic iron oxide nanocarriers via adsorptive surface masking. Biomaterials 2009; 30: 6780-7.
75. Chertok B, David AE, H uang Y, Yang VC. Glioma selectivity of magnetically targeted nanoparticles: a role of abnormal tumor hydrodynamics. J Control Release 2007; 122: 315-23. (Pubitemid 47404675)
76. ClinicalTrials.gov [In ternet]. Bethesda (MD): National Institutes of Health (US); 1993 - . Pre-operative staging of pancreatic cancer using superparamagnetic iron oxide magnetic resonance imaging (SPIO MRI) [cited 2010 September 12].; [about 3 p.]. Available from: http://clinicaltrials.gov/ct2/ show/NCT00920023 ClinicalTrials.gov Identifier NCT0090023.
77. Jain R, Dandekar P, Pa travale V. Diagnostic nanocarriers for sentinel lymph node imaging. J Control Release 2009; 138: 90-102.
78. Zhu L, Loo WT, Chow LW . Circulating tumor cells in patients with breast cancer: possible predictor of micro-metastasis in bone marrow but not in sentinel lymph nodes. Biomed Pharmacother 2005; 59: S355-8.
79. Cammareri P, Lombardo Y, Francipane MG, Bonventre S, Todaro M, Stassi G. Isolation and culture of colon cancer stem cells. Methods Cell Biol 2008; 86: 311-24.
80. Joo KM, Nam DH. Prospe ctive identification of cancer stem cells with the surface antigen CD133. Methods Mol Biol 2009; 568: 57-71.
81. Wang GY, Li Y, Yu YM, Yu B, Zhang ZY, Liu Y, et al. Detection of disseminated tumor cells in bone marrow of gastric cancer using magnetic activated cell sorting and fluorescent activated cell sorting. J Gastroenterol Hepatol 2009; 24: 299-306.
82. Multhoff G, Botzler C, Wiesnet M, Müller E, Meier T, Wilmanns W, et al. A stress-inducible 72-kDa heat-shock protein (HSP72) is expressed on the surface of human tumor cells, but not on normal cells. Int J Cancer 1995; 61: 272-9.
83. Johannsen M, Gneveckow U, Eckelt L, Feussner A, Waldöfner N, Scholz R, et al. Clinical hyperthermia of prostate cancer using magnetic nanoparticles: presentation of a new interstitial technique. Int J Hyperthermia 2005; 21: 637-47. (Pubitemid 41684238)
84. Maier-Hauff K, Rothe R, Scholz R, Gneveckow U, Wust P, Thiesen B, et al. Intracranial thermotherapy using magnetic nanoparticles combined with external beam radiotherapy: results of a feasibility study on patients with glioblastoma multiforme. J Neurooncol 2007; 81: 53-60. (Pubitemid 44963989)
85. FDA-Approved Drugs [Inte rnet]. Boston (MA): CenterWatch. 1995 - . FDA Approved Drugs for Oncology [cited 2010 September 14]; [about 7 p.]. Available from: .
86. Widder KJ, Morris RM, Po ore GA, Howard DP, Senyei AE. Selective targeting of magnetic albumin microspheres containing low-dose doxorubicin: total remission in Yoshida sarcoma-bearing rats. Eur J Cancer Clin Oncol 1983; 19: 135-9. (Pubitemid 13138726)
87. Lübbe AS, Bergemann C, R iess H, Schriever F, Reichardt P, Possinger K, et al. Clinical experiences with magnetic drug targeting: a phase I study with 4 -epidoxorubicin in 14 patients with advanced solid tumors. Cancer Res 1996; 56: 4686-93. (Pubitemid 26338071)
88. Alexiou C, Arnold W, Klei n RJ, Parak FG, Hulin P, Bergemann C, et al. Locoregional cancer treatment with magnetic drug targeting. Cancer Res 2000; 60: 6641-8.
89. Goodwin SC, Bittner CA, P eterson CL, Wong G. Single-dose toxicity study of hepatic intra-arterial infusion of doxorubicin coupled to a novel magnetically targeted drug carrier. Toxicol Sci 2001; 60: 177-83. (Pubitemid 32229837)
90. Koda J, Venook A, Walser E. A multicenter, phase I/II trial of hepatic intraarterial deliv ery of doxorubicin hydrochloride adsorbed to magnetic targeted carriers in patients with hepatocellular carcinoma. Eur J Cancer 2002; 38: S18.
91. Wilson MW, Kerlan RK, Fidelman NA, Venook AP, LaBerge JM, Koda J, et al. Hepatocellular car cinoma: regional therapy with a magnetic targeted carrier bound to doxorubicin in a dual MR imaging/ conventional angiography suite-initial experience with four patients. Radiology 2004; 230: 287-93. (Pubitemid 37549815)
92. ClinicalTrials.gov [Internet]. Bethesda (MD): National Institutes of Health (US); 1993 - . Safety and efficacy of doxorubicin adsorbed to magnetic beads Vs. IV doxorubicin in treating liver cancer [cited 2010 May 5]; [about 2 p.]. Available from: http://clinicaltrials.gov/ct/show/NCT00034333ClinicalTrial. gov Identifier: NCT00034333.
93. Kamensek U, Sersa G. Targeted gene therapy in radiotherapy. Radiol Oncol 2008; 42: 115-35.
94. Cemazar M, Jarm T, Sersa G. Cancer electrogene therapy with interleukin- 12. Curr Gene Ther 2010; 10: 300-11.
95. Krötz F, Sohn HY, Gloe T, Plank C, Pohl U. Magnetofection potentiates gene delivery to cult ured endothelial cells. J Vasc Res 2003; 40: 425-34. (Pubitemid 37465090)
96. Krötz F, de Wit C, Sohn HY, Zahler S, Gloe T, Pohl U, et al. Magnetofection-a highly effici ent tool for antisense oligonucleotide delivery in vitro and in vivo. Mol Ther 2003; 7: 700-10. (Pubitemid 36626250)
97. Jahnke A, Hirschberger J, Fischer C, Brill T, Köstlin R, Plank C, et al. Intratumoral gene d elivery of feIL-2, feIFN-gamma and feGM-CSF using magnetofection as a neoadjuvant treatment option for feline fibrosarcomas: a phase-I study. J Vet Med A 2007; 54: 599-606. (Pubitemid 350206008)
98. Hüttinger C, Hirschberger J, Jahnke A, Köstlin R, Brill T, Plank C, et al. Neoadjuvant gene de livery of feline granulocyte-macrophage colonystimulating factor using magnetofection for the treatment of feline fibrosarcomas: a phase I trial. J Gene Med 2008; 10: 655-67. (Pubitemid 351936538)
99. Lu Y, Madu CO. Viral-based gene delivery and regulated gene expression for targeted cancer thera py. Expert Opin Drug Deliv 2010; 7: 19-35.
100. Russ V, Wagner E. Cell and tissue targeting of nucleic acids for cancer gene therapy. Pharm Res 2007; 24: 1047-57. (Pubitemid 46798888)
101. Wolff JA, Malone RW, Williams P, Chong W, Acsadi G, Jani A, et al. Direct gene transfer into mo use muscle in vivo. Science 1990; 247: 1465-8.
102. Ardehali A, Fyfe A, Laks H, Drinkwater DC, Qiao JH, Lusis AJ. Direct gene transfer into donor h earts at the time of harvest. J Thorac Cardiovasc Surg 1995; 109: 716-20.
103. Schwarz ER, Speakman MT, Patterson M, Hale SS, Isner JM, Kedes LH, et al. Evaluation of the effects o f intramyocardial injection of DNA expressing vascular endothelial growth factor (VEGF) in a myocardial infarction model in the rat-angiogenesis and angioma formation. J Am Coll Cardiol 2000; 35: 1323-30. (Pubitemid 30206908)
104. Mueller C, Graessmann A, Graessmann M. Mapping of early SV40-specific functions by microinjecti on of different early viral DNA fragments. Cell 1978; 15: 579-85. (Pubitemid 9052426)
105. Neumann E, Schaefer-Ridder M, Wang Y, Hofschneider PH. Gene transfer into mouse lyoma cells by electroporation in high electric fields. EMBO J 1982; 1: 841-5.
106. Sanford JC, Klein TM, Wolf ED, Allen N. Delivery of substances into cells and tissues using a p article bombardment process. Particul Sci Technol 1987; 5: 27-37.
107. Bao S, Thrall BD, Miller DL. Transfection of a reporter plasmid into cultured cells by sonopora tion in vitro. Ultrasound Med Biol 1997; 23: 953-9. (Pubitemid 27349543)
108. Liu F, Song Y, Liu D. Hydrodynamics-based transfection in animals by systemic administration of plasmid DNA. Gene Ther 1999; 6: 1258-66.
109. McKnight T, Melechko A, Griffin G, Guillorn MA, Merkulov VI, Serna F, et al. Intracellular inte gration of synthetic nanostructures with viable cells for controlled biochemical manipulation. Nanotechnology 2003; 14: 551-6.
110. Ohlfest JR, Freese AB, Largaespada DA. Nonviral vectors for cancer gene therapy: prospects for integrating vectors and combination therapies. Curr Gene Ther 2005; 5: 629-41. (Pubitemid 43009507)
111. Morishita N, Nakagami H, Morishita R, Takeda S, Mishima F, Terazono B, et al. Magnetic nanopart icles with surface modification enhanced gene delivery of HVJ-E vector. Biochem Biophys Res Commun 2005; 334: 1121-6. (Pubitemid 41074690)
112. Mah C, Zolotukhin I, Fraites T, Dobson J, Batich C, Byrne B. Microspheremediated delivery of r ecombinant AAV vectors in vitro and in vivo. Mol Ther 2000; 1: 239S.
113. Xenariou S, Griesenbach U, Ferrari S, Dean P, Scheule RK, Cheng SH, et al. Using magnetic force s to enhance non-viral gene transfer to airway epithelium in vivo. Gene Ther 2006; 13: 1545-52. (Pubitemid 44567151)
114. Boussif O, Lezoualc h F, Zanta MA, Mergny MD, Scherman D, Demeneix B, et al. A versatile vector for gene and oligonucleotide transfer into cells in culture and in vivo: polyethylenimine. Proc Natl Acad Sci U S A 1995; 92: 7297-301.
115. Pan X, Guan J, Yoo JW, Epstein AJ, Lee LJ, Lee RJ. Cationic lipid-coated magnetic nanoparticles associated with transferrin for gene delivery. Int J Pharm 2008; 358: 263-70.
116. Xiang JJ, Nie XM, Tang JQ, Wang YJ, Li Z, Gan K, et al. In vitro gene transfection by magnetic iron oxide nanoparticles and magnetic field increases transfection efficiency. Zhonghua Zhong Liu Za Zhi 2004; 26: 71-4.
117. Yang SY, Sun JS, Liu CH, Tsuang YH, Chen LT, Hong CY, et al. Ex vivo magnetofection with magnet ic nanoparticles: a novel platform for nonviral tissue engineering. Artif Organs 2008; 32: 195-204.
118. Ino K, Kawasumi T, Ito A, Honda H. Plasmid DNA transfection using magnetite cationic liposomes for construction of multilayered gene-engineered cell sheet. Biotechnol Bioeng 2008; 100: 168-76. (Pubitemid 351579027)
119. Kamau Chapman SW, Hassa PO, Koch-Schneidemann S, von Rechenberg B, Hofmann-Amtenbrink M, Steitz B, et al. Application of pulsed-magnetic field enhances non-viral gene delivery in primary cells from different origins. J Magn Magn Mater 2008; 320: 1517-27.
120. Chorny M, Polyak B, Alferiev IS, Walsh K, Friedman G, Levy RJ. Magnetically driven plasmid DNA delivery with biodegradable polymeric nanoparticles. FASEB J 2007; 21: 2510-9. (Pubitemid 47230680)
121. Kamau SW, Hassa PO, Steitz B, Petri-Fink A, Hofmann H, Hofmann- Amtenbrink M, et al. Enhancement of the efficiency of non-viral gene delivery by application of pulsed magnetic field. Nucleic Acids Res 2006; 34: e40.
122. McBain S, Griesenbach U, Xenariou S, Keramane A, Batich CD, Alton EWFW, et al. Magnetic nanopar ticles as gene delivery agents: enhanced transfection in the presence of oscillating magnet arrays. Nanotechnology 2008; 19: 1-5.
123. Maass G, Schweighoffer T, Berger M, Schmidt W, Herbst E, Zatloukal K, et al. Tumor vaccines: ef fects and fate of IL-2 transfected murine melanoma cells in vivo. Int J Immunopharmacol 1995; 17: 65-73.
124. Schmidt W, Schweighoffer T, Herbst E, Maass G, Berger M, Schilcher F, et al. Cancer vaccines: t he interleukin 2 dosage effect. Proc Natl Acad Sci U S A 1995; 92: 4711-4.
125. Kircheis R, Küpcü Z, Wallner G, Wagner E. Cytokine gene-modified tumor cells for prophylactic a nd therapeutic vaccination: IL-2, IFN-gamma, or combination IL-2 + IFN-gamma. Cytokines Cell Mol Ther 1998; 4: 95-103. (Pubitemid 28356518)